PT  - JOURNAL ARTICLE
AU  - PAOLA SECCHIERO
AU  - FEDERICA CORALLINI
AU  - GABRIELLA CASTELLINO
AU  - ALESSANDRA BORTOLUZZI
AU  - LORENZO CARUSO
AU  - SERENA BUGATTI
AU  - RAFFAELLA BOSCO
AU  - MAURIZIO MONTECUCCO
AU  - FRANCESCO TROTTA
TI  - Baseline Serum Concentrations of TRAIL in Early Rheumatoid Arthritis: Relationship with Response to Disease-modifying Antirheumatic Drugs
AID  - 10.3899/jrheum.091363
DP  - 2010 Jul 01
TA  - The Journal of Rheumatology
PG  - 1461--1466
VI  - 37
IP  - 7
4099  - http://www.jrheum.org/content/37/7/1461.short
4100  - http://www.jrheum.org/content/37/7/1461.full
SO  - J Rheumatol2010 Jul 01; 37
AB  - Objective. To assess the relationship between serum concentrations of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and osteoprotegerin (OPG) and the therapeutic response to disease-modifying antirheumatic drugs (DMARD) in patients with early rheumatoid arthritis (RA). Methods. Circulating levels of TRAIL and its soluble receptor OPG were measured by ELISA in paired serum samples obtained from 66 patients with early RA at their first visit (baseline) and after 1 year of therapy. Levels of TRAIL and OPG were analyzed in relation to the clinical response, defined by the 28-joint count Disease Activity Score (DAS28). Results. Both serum TRAIL and OPG increased after DMARD therapy. Baseline levels of TRAIL, but not OPG, were significantly higher (p < 0.05) in the patients that achieved a clinical response by DAS28 after 1 year of therapy, versus patients without clinical response to DMARD. Baseline serum levels of TRAIL were higher (p < 0.01) in rheumatoid factor-negative patients. Conclusion. Our data suggest that the basal level of circulating TRAIL is an important determinant in the therapeutic response to DMARD in patients with early RA.